GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection

• New offering provides an all-in-one AI platform optimized for mammography, that seamlessly integrates artificial intelligence (AI) applications from iCAD to aid clinicians in breast cancer detection as well as breast density assessment and notification.

CHICAGO–(BUSINESS WIRE)–Today GE HealthCare (Nasdaq: GEHC) announced the release of a new, all-in-one platform of artificial intelligence (AI) apps to support clinicians with breast cancer detection and improved workflow productivity called MyBreastAI Suite*. With this initial release, MyBreastAI Suite integrates three AI applications from iCAD including ProFound AI for DBT, SecondLook for 2D Mammography and PowerLook Density Assessment to help support early detection and improve patient outcomes, as well as help radiology departments improve operational productivity.

As the global cancer burden rises, radiologists face increasing challenges such as burnout, workforce attrition, and patient backlogs, placing strain on and testing the resiliency of health systems today. In ongoing efforts to combat breast cancer, the healthcare community remains committed to early detection by leveraging methods, like screening mammography, that have proven to be effective in identifying early breast cancers and reducing breast cancer-specific mortality.¹ However, with breast cancer now surpassing lung cancer as the most commonly diagnosed cancer worldwide,² clinicians are seeking tools that can address issues related to access, burnout, variability, equity, and cost in breast imaging to elevate and enhance the detection and diagnosis of breast cancer.

The introduction of MyBreastAI Suite aims to address these challenges by providing an all-in-one platform that can seamlessly deploy AI to breast imaging workflow. With this initial release, MyBreastAI Suite integrates three AI applications from iCAD’s ProFound Breast Health Suite, including:

• ProFound AI for DBT: Trained with one of the largest available 3D image datasets, ProFound AI for DBT provides radiologists with crucial information, such as lesion Certainty of Finding and Case Scores, which assists in prioritizing caseloads, clinical decision-making, and may help reduce burnout.³
• SecondLook for 2D Mammography: The SecondLook Computer-Aided Detection (CAD) system for mammography is intended to identify and mark regions of interest on screening and diagnostic mammograms from GE HealthCare’s full-field digital mammography (FFDM) systems to bring them to the attention of the radiologist after an initial reading has been completed.⁴
• PowerLook Density Assessment: This tool helps to standardize breast density assessment and reduce variability across multiple radiologists;⁵ simplify and standardize reporting and stratification for clinicians;⁶and enables clinicians to provide women with accurate and reliable breast density assessments based on AI mammogram analysis.⁷

Studies show that the deployment of these digital solutions can assist in prioritizing case load and clinical decision-making. For example, iCAD reader study shows that radiologists reading with ProFound AI for DBT increases reader sensitivity by 8%, increases reader specificity by 6.9%⁸ and decreases reading time by up to 52% compared to without.⁹

“As part of GE HealthCare’s ongoing commitment to transform healthcare and improve patient outcomes, we continue to explore how we can leverage the power of AI in mammography to support the early detection of breast cancer,” says Pooja Pathak – Vice President and General Manager of Mammography. “As screening guidelines continue to evolve and more attention is given to personal risk factors such as breast density, these kinds of tools are an important and exciting addition to our comprehensive portfolio of breast imaging technologies.”

“Through this new all-in-one AI platform designed to offer radiologists enhanced clinical decision support and streamlined workflows, clinicians will be able to deliver more timely, accurate and personalized breast care in their practices today. We know that early detection is key and AI solutions show great promise in advancing breast cancer screening and transforming workflow for radiologists,” says Mario Lois – General Manager of AI for Women’s Health.

MyBreastAI Suite will first be available in the United States and will be distributed, installed and supported by GE HealthCare as part of the company’s Senographe Pristina mammography portfolio.

This product may not be available in your country or region. Please contact your GE HealthCare representative for more information.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.

Follow us on Facebook, LinkedIn, Twitter, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

_____________________________________________________

*MyBreastAI suite is a commercial offering that includes an AI platform optimized for Mammography, ProFound AI for DBT, SecondLook for 2D Mammography and PowerLook Density Assessment. These three applications are provided by iCAD. MyBreastAI Suite is compatible with the latest versions of iCAD, Inc. as of November 14, 2023.

¹ https://www.ncbi.nlm.nih.gov/books/NBK222338/

²Bashar, MD Abu; Begam, Nazia1. Breast cancer surpasses lung cancer as the most commonly diagnosed cancer worldwide. Indian Journal of Cancer 59(3):p 438-439, Jul–Sep 2022. | DOI: 10.4103/ijc.IJC_83_21

³iCAD data on file. FDA filing: K203822. Standalone performance varies by vendor. FDA Cleared and CE Mark Pending. Reading times may vary based on the specific functionality of the viewing application used for interpretation

⁴iCAD labelling and user manual, DTM 103 – Revision C.

⁵ iCAD labelling and user manuel, DTM103 – Revision C.

⁶iCAD labelling and user manual, DTM135-1, DTM156-3, DTM184 rev1.

⁷iCAD labelling and user manual, DTM135-1, DTM156-3, DTM184 rev1.

⁸ Reader performance with Profound AI compared to performance without. iCAD reader study: Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096. iCAD labelling and user manual, DTM160 rev C.

⁹iCAD reader study: Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096. iCAD labelling and user manual, DTM160 rev C. Reading times may vary based on the specific functionality of the viewing application used for interpretation.

Contacts

Emily Dalton Niles

Emily.niles@ge.com